文献速递急性肾损伤肾小球疾病

TNFα阻断在ANCA相关血管炎和肾小球肾炎中有作用吗?

Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

本文综述TNFα在ANCA相关血管炎(AAV)病理生理中的作用及TNFα阻断的治疗潜力。动物模型显示抗TNFα抗体可改善肾损伤,但WGET试验显示依那西普联合标准治疗无获益;作者认为WGET设计及依那西普与抗TNFα抗体的生物学差异不能排除抗TNFα抗体在急性肾AAV中的应用,难治性患者中有应答报道,建议进一步研究。

要点

  • TNFα可诱导中性粒细胞表达PR3和MPO,为ANCA效应提供启动条件。
  • 动物模型中TNFα阻断可改善肾小球损伤和白细胞迁移。
  • WGET试验显示依那西普联合标准治疗无获益,但不能排除抗TNFα抗体。

核心结论

  • TNFα在AAV病理生理中起重要作用,TNFα阻断在动物模型中有效,但WGET试验未显示依那西普获益。
  • WGET的设计及依那西普与抗TNFα抗体的生物学差异不能排除抗TNFα抗体在急性肾AAV中的应用。
  • 难治性AAV患者中有抗TNFα抗体应答的临床报道,值得进一步研究TNFα阻断在AAV中的作用。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • AAV患者白细胞和肾组织中TNFα mRNA表达增加。
  • TNFα可诱导白细胞膜表达PR3和MPO,从而启动ANCA效应。
  • 抗GBM肾炎(肾毒性肾炎)啮齿模型中,TNFα增强肾小球损伤,可溶性TNFα受体或抗TNFα抗体改善疾病。
  • TNFα缺陷小鼠对肾毒性肾炎有保护作用,该效应主要依赖固有肾脏细胞。
  • 抗MPO抗体诱导的小鼠肾小球肾炎可被LPS增强,抗TNFα抗体可阻断该效应;MPO诱导的大鼠实验性自身免疫血管炎中,抗TNFα抗体改善肾脏病理并减少白细胞迁移。

临床怎么用

  • 目前证据不支持在AAV标准治疗中常规加用依那西普。
  • 对常规治疗难治的AAV患者,抗TNFα抗体可能是有待进一步验证的选择。

局限性

  • WGET试验的设计存在局限,且依那西普与抗TNFα抗体存在显著生物学差异。
  • 支持抗TNFα抗体用于难治性AAV的临床研究多为小样本报道,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumour necrosis factor alpha (TNFα) is a cytokine that is pivotal in the inflammatory response. Blockade of TNFα has been shown to be effective in a number of human autoimmune diseases, including rheumatoid arthritis, raising the question of whether this approach may be effective in inflammatory kidney disease, such as ANCA-associated vasculitis (AAV). In AAV, there is considerable evidence for the role of TNFα in the pathophysiology of disease, including increased expression of TNFα mRNA in leucocytes and in renal tissue. Importantly, TNFα can induce leucocyte cell membrane expression of the autoantigens involved in vasculitis [proteinase 3 and myeloperoxidase (MPO)], thus priming cells for the effects of ANCA. In rodent models of anti-GBM disease (nephrotoxic nephritis), TNFα enhances glomerular injury and TNFα blockade using soluble TNFα receptor or anti-TNFα antibody ameliorates disease. Mice deficient in TNFα are protected from nephrotoxic nephritis and this effect is dependent mainly on intrinsic renal cells. A mouse model of anti-MPO antibody-induced glomerulonephritis is enhanced by LPS, and this effect is blocked by anti-TNFα antibody. In a rat model of AAV induced by MPO (experimental autoimmune vasculitis), anti-TNFα antibody improves renal pathology and also reduces leucocyte transmigration, as shown by intravital microscopy. In clinical studies, the Wegener's Granulomatosis Etanercept Trial (WGET) showed no benefit of additional etanercept versus standard therapy. However, there are several reasons why the results of the WGET study do not rule out the use of anti-TNFα antibody in acute renal AAV, including the study design and the considerable biological differences between the effects of etanercept and anti-TNFα antibody. There are several clinical studies demonstrating a response to anti-TNFα antibody in patients with AAV refractory to conventional treatment, and in some of these, the addition of anti-TNFα antibody was the only change in treatment. We suggest that further investigation of TNFα blockade in AAV is warranted.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. McAdoo SP, Pusey CD. Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis? Nephrol Dial Transplant. 2017. PMID: 28391344. doi:10.1093/ndt/gfw361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。